Nonsteroidal anti-inflammatory drugs use in patients with chronic kidney disease are often prescribed from different clinicians than those who diagnosed them.


Journal

Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369

Informations de publication

Date de publication:
08 2020
Historique:
received: 14 11 2019
revised: 23 04 2020
accepted: 23 04 2020
pubmed: 16 5 2020
medline: 16 6 2021
entrez: 16 5 2020
Statut: ppublish

Résumé

When prescribing nonsteroidal anti-inflammatory drugs (NSAIDs) for chronic kidney disease (CKD), patients' pathology and concomitant medications should be considered. In our pharmaceutical experience, NSAIDs are often prescribed by departments that are different from those that diagnosed CKD. That is, NSAIDs may be prescribed for patients without the advice of the clinicians who diagnosed them. In this study, we aimed to elucidate how frequently such cases occur. We used the large health insurance claims database constructed by JMDC Inc., Tokyo. We evaluated the proportions of CKD diagnosis and NSAID prescription by different clinical departments and institutions. A total of 224 014 out-patients were included in the analysis; they were divided into CKD (n = 1501) and non-CKD groups (n = 222 513). The internal medicine departments diagnosed CKD most frequently (74.8% of the patients) and surgical departments rarely diagnosed CKD. However, the proportion of prescribed NSAIDs was high in other departments, especially surgical departments. In the CKD group, 50.4% of the patients received CKD diagnosis and NSAID prescription from different clinical departments; 72.8% of the patients received a diagnosis and prescription from different medical institutions. Our study revealed that NSAIDs are often prescribed to patients with CKD from different clinicians than those who diagnosed them.

Identifiants

pubmed: 32410339
doi: 10.1002/pds.5027
doi:

Substances chimiques

Anti-Inflammatory Agents, Non-Steroidal 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

873-880

Informations de copyright

© 2020 John Wiley & Sons Ltd.

Références

Adams DH, Howie AJ, Michael J, McConkey B, Bacon PA, Adu D. Non-steroidal anti-inflammatory drugs and renal failure. Lancet. 1986;1:57-60.
Sandler DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med. 1991;115:165-172.
Gooch K, Culleton BF, Manns BJ, et al. NSAID use and progression of chronic kidney disease. Am J Med. 2007;120:280.e1-280.e7.
Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106:13S-24S.
Kidney disease: improving global outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1-150.
Japanese Society of Nephrology. Evidence-based clinical practice guidelines for chronic kidney disease. J Japanese Soc Nephrol. 2018;60:94.
Plantinga L, Grubbs V, Sarkar U, et al. Nonsteroidal anti-inflammatory drug use among persons with chronic kidney disease in the United States. Ann Fam Med. 2011;9:423-430.
Hull S, Mathur R, Dreyer G, Yaqoob MM. Evaluating ethnic differences in the prescription of NSAIDs for chronic kidney disease: a cross-sectional survey of patients in general practice. Br J Gen Pract. 2014;64:e448-e455.
Heleniak Z, Cieplińska M, Szychliński T, et al. Nonsteroidal anti-inflammatory drug use in patients with chronic kidney disease. J Nephrol. 2017;30:781-786.
Tachi T, Saito K, Esaki H, et al. Medical and economic factors influencing generic drug use in the Japanese public health system: influencing factors in different populations. Int J Health Plann Manage. 2018;33:489-501.
Tsutsumi M, Shaku F, Ozone S, Sakamoto N, Maeno T. Reasons for the reference of clinic visits to self-medication by common cold patients in Japan. J Gen Fam Med. 2017;18:336-340.
Japan Medical Data Center. https://www.jmdc.co.jp/en/ (Accessed August 28, 2019).
Kim H-Y. Statistical notes for clinical researchers: chi-squared test and Fisher's exact test. Restor Dent Endod. 2017;42:152-155.
Kristensen SL, Fosbøl EL, Kamper AL, et al. Use of nonsteroidal anti-inflammatory drugs prior to chronic renal replacement therapy initiation: a nationwide study. Pharmacoepidemiol Drug Saf. 2012;21:428-434.
Ushida T, Matsui D, Inoue T, et al. Recent prescription status of oral analgesics in Japan in real-world clinical settings: retrospective study using a large-scale prescription database. Expert Opin Pharmacother. 2019;20:2041-2052.
Chiu HY, Huang HL, Li CH, et al. Increased risk of chronic kidney disease in rheumatoid arthritis associated with cardiovascular complications - a national population-based cohort study. PLoS One. 2015;10:e0136508.
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in patients with type 2 diabetes and microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345:870-878.
Hsu TW, Liu JS, Hung SC, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174:347-354.
Wakasugi M, Kazama JJ, Narita I. Secular trends in end-stage kidney disease requiring renal replacement therapy in Japan: Japanese Society of Dialysis Therapy Registry data from 1983 to 2016. Nephrology (Carlton). 2020;25:172-178.
United Nations Department of Economic and Social Affairs Population Dynamics. https://population.un.org/wpp/Publications/Files/WPP2019_DataBooklet.pdf (accessed April 3, 2020).

Auteurs

Shungo Imai (S)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Kenji Momo (K)

Department of Hospital Pharmaceutics, School of Pharmacy, Showa University, Tokyo, Japan.

Hitoshi Kashiwagi (H)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.

Takayuki Miyai (T)

Graduate School of Life Science, Hokkaido University, Sapporo, Japan.

Mitsuru Sugawara (M)

Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan.
Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.

Yoh Takekuma (Y)

Department of Pharmacy, Hokkaido University Hospital, Sapporo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH